CCCC C4 Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%
Returns
ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M |
| R&D expense | $104.24M | $110.64M | $117.71M | $117.84M | $94.67M |
| SG&A expense | $36.20M | $42.12M | $42.08M | $42.79M | $33.25M |
| Operating income | -$115.22M | -$119.61M | -$139.03M | -$129.53M | -$82.13M |
| Pretax income | -$104.87M | -$105.19M | -$131.21M | -$128.18M | -$83.89M |
| Income tax | $121,000 | $131,000 | $1.28M | $0 | $0 |
| Net income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M |
| EBITDA | -$113.26M | -$117.80M | -$137.15M | -$127.86M | -$80.64M |
| EPS (basic) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 |
| EPS (diluted) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 |
| Weighted avg. shares (diluted) | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M |
| Balance sheet | |||||
| Cash & equivalents | $74.60M | $58.94M | $130.03M | $33.03M | $79.40M |
| Short-term investments | — | — | — | — | $233.16M |
| Receivables | $2.40M | $3.10M | $11.80M | $1.47M | $5.72M |
| Current assets | $258.11M | $257.77M | $271.19M | $287.56M | $325.69M |
| PP&E, net | $4.74M | $5.84M | $7.13M | $7.40M | $3.11M |
| Total assets | $359.07M | $349.60M | $376.45M | $430.84M | $506.76M |
| Current liabilities | $33.03M | $45.18M | $42.77M | $44.55M | $51.25M |
| Short-term debt | — | — | $0 | $2.29M | $0 |
| Long-term debt | — | — | $0 | $9.20M | $10.77M |
| Total debt | — | — | $0 | $11.48M | $10.77M |
| Total liabilities | $102.49M | $133.62M | $130.34M | $141.61M | $117.16M |
| Shareholders' equity | $256.59M | $215.99M | $246.11M | $289.23M | $389.61M |
| Net debt | — | — | -$130.03M | -$21.55M | -$68.64M |
| Shares outstanding | 96.91M | 70.63M | 60.47M | 48.97M | 48.69M |
| Cash flow statement | |||||
| Operating cash flow | -$98.69M | -$65.16M | -$106.84M | -$105.94M | -$86.97M |
| Capital expenditure | $607,000 | $180,000 | $1.71M | $5.50M | $1.28M |
| Free cash flow | -$99.30M | -$65.34M | -$108.55M | -$111.44M | -$88.24M |
| Investing cash flow | -$8.60M | -$51.27M | $158.35M | $58.42M | -$189.34M |
| Financing cash flow | $126.40M | $45.34M | $45.49M | $1.15M | $171.40M |
| Depreciation & amortization | $1.96M | $1.82M | $1.88M | $1.68M | $1.49M |
| Stock-based compensation | $19.10M | $29.66M | $27.23M | $30.02M | $21.51M |
| Share buybacks | $193,000 | $194,000 | $110,000 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.